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Abstract
‘Personalized medicine’ might sound like the very antithesis of population science and public 
health, with the individual taking the place of the population. However, in practice, personalized 
medicine generates heavy investments in the population sciences – particularly in data-sourcing 
initiatives. Intensified data sourcing implies new roles and responsibilities for patients and 
health professionals, who become responsible not only for data contributions, but also for 
responding to new uses of data in personalized prevention, drawing upon detailed mapping 
of risk distribution in the population. Although this population-based ‘personalization’ of 
prevention and treatment is said to be about making the health services ‘data-driven’, the 
policies and plans themselves use existing data and evidence in a very selective manner. It is 
as if data-driven decision-making is a promise for an unspecified future, not a demand on its 
planning in the present. I therefore suggest interrogating how ‘promissory data’ interact with 
ideas about accountability in public health policies, and also with the data initiatives that the 
promises bring about. Intensified data collection might not just be interesting for what it allows 
authorities to do and know, but also for how its promises of future evidence can be used to 
postpone action and sidestep uncomfortable knowledge in the present.
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Introduction
‘Personalized medicine’ is one of several names for various streams of overlapping and 
related ideas also known as genomic, precision, targeted, stratified or differentiated 
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medicine (Hedgecoe, 2004; Prainsack, 2017; Reardon, 2011; Tutton, 2012). Each of 
these names holds several meanings and the various streams refer to complementary 
and sometimes competing attempts at individualizing medical treatment and preven-
tion. During the past couple of years, many researchers and politicians have begun talk-
ing about ‘P4 Medicine’ as a catchy term to refer to the wider assemblage of personalised 
medicine as a matter of making medicine predictive, preventive, personalized, and par-
ticipatory (Hood and Flores, 2012). As De Grandis and Halgunset (2016) argue, these 
are all ‘future-oriented concepts’, where their vagueness is instrumental to their politi-
cal efficacy.
Personalized medicine might sound like the very antithesis of public health and the 
population sciences, focusing on individuals rather than populations. However, in this 
article I show that personalized medicine fuels heavy investments into the population 
health sciences and uses population data to guide individuals. Personalized medicine 
does not imply a shift from population to individual; rather, it generates new ways of 
inscribing the population in the individual and of letting individuals contribute in new 
ways to the population. Personalized medicine stimulates ‘intensified data sourcing’ 
(Hoeyer, 2016), by which I mean attempts at getting more data, of better quality, from 
more people – despite disagreements about uses of the data. Proponents of personalized 
medicine require access to data from large-scale genomic research projects, as well as 
data collected in the course of routine care (Green et al., 2019). Clinicians have always 
used patient data as learning opportunities, but initiatives aimed at personalized medi-
cine intensify data collection and pooling – and in consequence confront patients with 
heightened responsibilities for contributing personal data to shared resources (Prainsack, 
2015). In the Danish case I present here, data-pooling facilitates not only research and 
clinical experimentation with personalized treatment, but also stratification of popula-
tion groups and personalized prevention targeting at-risk individuals in general practice. 
It shifts expectations for both general practitioners (GPs) and patients, and reconfigures 
ideas about health, illness and the role and nature of evidence in documenting effects of 
interventions.
The rise of personalized medicine should be understood in the context of changing 
socio-technical practices in the governance of public health, including how attributions 
of responsibility are made in relation to data-based decision making. Governmental 
accountability has long been associated with documentation, transparency and responsi-
ble means of enforcement (Bessette, 2001). Accountability denotes an institutional allo-
cation of responsibility and systems for controlling responsibilities. Current accountability 
regimes need data and typically rely on what Porter (1995) calls ‘trust in numbers’. Key 
studies, however, have questioned the ability of quantitative data to underpin systems of 
responsibility (Power, 1997; Strathern, 2000; Wiener and Kayser-Jones, 1989). As data 
can be open to multiple interpretations, it has also been argued that data intensification 
can lead to a more (rather than less) ambiguous allocation of responsibility (Jerak-
Zuiderent and Bal, 2011). Furthermore, there is an enduring tension between understand-
ings of accountability as ‘from nowhere and for everyone’ (as in multi-use databases) 
and ‘from somewhere and for someone’ (as in everyday clinical care) (Jerak-Zuiderent, 
2015: 412). This tension has increased with the digitization of medical records, because 
digitization facilitates easy reuse of data and allows the authorities to re-conceptualize 
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the health records as audit tools and not just clinical memory practices (Winthereik et al., 
2007). We are now facing a form of second-generation digitization, where data sharing 
for ever more purposes are made possible through data centralization. Personalized treat-
ment and prevention are among the additional purposes that digitalized data centraliza-
tion is aimed at facilitating.
Intensified data sourcing might also affect accountability in ways other than simply 
adding purposes. In fact, my key argument is that data intensification is becoming a way 
for public authorities to respond to a wider set of problems related to budget restraints 
and demographic challenges, problems for which they basically have no solutions. In 
this situation, data increasingly come to serve as a promise of future accountability. They 
should be thought of as promissory data. Instead of doing something today, authorities 
postpone action until more data has been accumulated. Data serve as promises of future 
action. Data initiatives allow authorities to present themselves as responding to problems 
while in effect they are merely promising future action – once enough data has allowed 
identification of new solutions. My point is we might misunderstand the politics of data 
intensification if we think it all relates to what authorities can do and know with data. In 
some instances, it might be just as important for authorities that data collection can be 
used to avoid action. They can postpone action while ‘waiting for more data’. To under-
stand how personalized medicine reconfigures public health in Denmark we therefore 
need to understand how it interacts with wider initiatives of data sourcing and how data 
are used to hold (or, in some cases, not hold) individuals and authorities accountable for 
their actions.
Locating the field of personalized medicine and prevention 
in Denmark
Denmark is a high-income country in northern Europe with just 5.7 million inhabitants 
and with universal tax-financed coverage of medical care and a range of other welfare 
benefits. Though there are some out-of-pocket payments for pharmacy prescriptions 
and dental care, there is a high degree of social security (Vallgårda, 2016). Denmark is 
also characterized by a very elaborate IT infrastructure, digitized health services, and 
very elaborate national registries collecting structured data on all citizens from birth to 
grave (Thygesen and Ersbøll, 2011). Everyone in Denmark is allocated a personal iden-
tity number at birth or immigration. This is used in all interactions with public authori-
ties (and for many private services). Practically all data are digitized, and thanks to the 
identification number they can be related to each other, not by probability (as in e.g. 
Scotland), but by actual reference to each individual. Many of these features also char-
acterize the other Nordic countries and there is a form of national branding competition 
among them to attract international research investments with claims from each country 
about having unique data sources for the population sciences (Tarkkala and Tupasela, 
2018; Tupasela, 2017).
‘That sounds absolutely outrageous!’ is a reaction I have had when describing the 
Danish registry system to academic colleagues outside the Nordic countries. Often, peo-
ple have already read my descriptions, but it is only in the course of a subsequent dia-
logue they seem to realize the opportunities for data tracking that result from assigning 
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each individual an identity number, which is then used in all interactions with authorities 
and most commercial services (sports, transport, telecommunication etc.). ‘You should 
write about that!’ they then say, and only when re-reading my draft do they realize what 
it actually means. The number assigned to each citizen at birth or upon immigration is 
kept in a registry that tracks the place of residence and family relations of all citizens at 
all times. By using the same number in all interactions with the public authorities, it is 
possible to track all citizens with respect to their medical diagnoses and treatments 
throughout life, their cause of death, and all publicly mediated services including hous-
ing, income, and education. In consequence, the whole country has been described as one 
big ‘cohort study’ and an ‘epidemiologist’s dream’ (Bauer, 2014; Frank, 2000, 2003). 
Data from public registries can be used for administrative and research purposes without 
informed consent, and this tracking of citizens is seen as relatively uncontroversial by the 
public, not least because it facilitates easy access to and coordination of services for most 
citizens (Hoeyer, 2018).
My investigation of personalized medicine in Denmark explores this data infrastruc-
ture and its current reconfigurations. My approach takes leads from work in science and 
technology studies (STS) on personalized medicine (Hedgecoe, 2004; Reardon, 2011; 
Tutton, 2012), big data assemblages (Cool, 2016; Hogle, 2016a, 2019), data-intensive 
population sciences (Ackerman et al., 2016; Bauer, 2013; Moriera and Palladino, 2011) 
and critical interrogations of public health (Armstrong, 2017; Bauer, 2014; Dumit, 2012). 
As a native Dane, most of my work could be seen as a form of ‘ethnography at home’ 
(Jackson, 1987), and in fact I often find myself serving as both ethnographer and data 
subject. When I go to the doctor and undertake everyday activities such as sport or gro-
cery shopping, I produce the kind of data traces related to my own personal identity 
number that data-intensive medicine is eager to accumulate. However, participation in 
these mundane activities reveal little about the emerging assemblage of personalized 
medicine per se. I do not ‘experience’ the infrastructure, and rarely see the data. I am thus 
submerged in the field while also being strangely expelled from it. I am both at its centre 
and unable to locate it anywhere.
The problem of access reflects a more basic analytical problem: Where is the future of 
personalized medicine taking shape? Taking an ethnographic response to documents 
(Riles, 2006), I have been tracing policy papers relating to personalized medicine and 
their references to the scientific literature. Gradually, I have come to see policy docu-
ments, along with conferences, meetings, workshops and public hearings as places where 
competing futures of medicine are articulated in ways that shape the present, irrespective 
of the predictive value of the promises made (Brown and Michael, 2003; Fortun, 2008; 
Hedgecoe, 2004; Petersen, 2019). During the past three years I have participated in more 
than twenty conferences and meetings in Denmark on personalized medicine and big data, 
mostly just as an audience member but on three occasions also as speaker invited to com-
ment on ‘ethical’ issues. Most of the conferences were advertised as academic events 
though some where marketed as networking opportunities aimed also at industry. At such 
conferences it is impossible to get an informed consent from every participant, and for 
ethical reasons I therefore refrain below from giving too many details that could identify 
speakers or commentators. One of the striking features of the conferences is the sense of 
convergence; there is tremendous agreement about being on the brink of something new, 
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about needed investment, and about the considerable ‘potential’ in personalizing medicine 
(Taussig et al., 2013). General references to public statements at the conferences are ways 
of communicating this agreement in an ethically sensitive way. To further understand the 
data-sourcing initiatives on which personalized medicine depend, I have also undertaken 
interviews with people working as clinicians or data managers at the clinical or adminis-
trative level. The quotes from texts and interviews that I present in the following have all 
been translated from Danish, and italics have been used to indicate informants’ 
emphasis.1
Seen from an international perspective, the average Dane is relatively privileged. 
Public debates in Denmark, however, tend to focus on crisis and the need for reform to 
sustain existing levels of care. A ‘good crisis’ is usually conducive for public acceptance 
of reform, and no doubt some stakeholders use this rhetoric consciously. Nevertheless, 
the national health system also faces very real problems. Contributing to the sense of 
urgency are expensive new treatment options and demographic transitions towards an 
aging population with rising rates of multimorbidity and chronic illnesses. In this mix of 
being at the frontier of e-health innovation and data pooling, while facing economic chal-
lenges, personalized medicine has emerged as an ambiguous figure, simultaneously rep-
resenting challenge, rescue and opportunity. But to understand this properly, we first 
need to understand better why proponents of personalized medicine find the Danish 
information infrastructure for population data so attractive; that is, why does personal-
ized medicine tend to generate demands for the types of population data that Denmark 
has in such abundance?
Personalized medicine means investments in intensified 
data sourcing
In a relatively recent but already widely-cited commentary in Nature, Nicholas Schork 
(2015) from the Craig Venter Institute argues that the classical Randomized Clinical Trial 
(RCT) is obsolete. We need a new system of approval, he suggests, aimed at cutting the 
expenditure associated with testing many people on few factors. Instead of the RCT, we 
should test few people in relation to many factors. The aim is to arrive at a form of medi-
cine that works for the individual. He is not particularly clear on how statistics should 
work with many factors and low numbers, and says little about how to acquire general 
insights into unique conditions (Abettan, 2016). The idea of predictions at the level of the 
individual has long been seen as statistically absurd by biostatisticians (Henderson and 
Keiding, 2005). From an STS perspective, Tutton (2014: 56) argues that individualiza-
tion cannot mean finding the right treatment for the individual per se; it must imply 
assigning individuals to new groups. This would imply that personalization in assess-
ments of medical effect is more like a continuation of the gradual developments of the 
RCT that have come to take into account differences in gender, race and age (Epstein, 
2003). However, Schork (2015) not only envisages new ways of grouping trial subjects; 
he also wants to begin ‘transforming everyday clinical care into solid N-of-1 trials’ (p. 
611). In other words, Schork suggests that data should be harvested in the course of daily 
treatment, and that all patients should be regarded as research participants (Hogle, 
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2016b).2 With N-of-1 trials in daily clinical practice, Schork thus imagines individuals 
contributing to the population in the hope that population data can guide their own and 
other patients’ treatment. Such plans necessitate a centralized IT infrastructure for health 
data (Carusi, 2016). Heavy investments in collection, storage and use of health data are 
therefore key components of the personalized medicine agenda (Prainsack, 2015).
In the period 2007–2013, the European Union (EU) invested 1 billion Euros in per-
sonalized medicine just within the 7th Framework Programme. On top of this came cor-
porate and national research investments. To facilitate access to the needed data, the EU 
also funded harmonization of biobanks and data infrastructures to allow easier pooling 
of data (General Secretariat of the Council, 2016). In 2015, the Council of the EU fur-
thermore adopted a strategy paper on personalized medicine according to which member 
states should work to ‘support the standardisation and networking of biobanks to com-
bine and share resources’ and ‘promote the interoperability of electronic health records 
to facilitate their use for public health and research’ (General Secretariat of the Council, 
2015: 7). In January 2019, the EU invested an additional 21 million Euros in the con-
struction of an interoperable electronic health record through the Horizon 2020 program 
(and invited STS scholars on board to help make the prototype ‘citizen centred’; see 
Smart4Health, 2019). One of the data specialists I interviewed had some experience with 
previous attempts in this field and stated that while the full integration of European medi-
cal records will never work in practice, the political ambition is nevertheless clear. In the 
United Kingdom, the then Prime Minister Cameron personally worked to establish the 
100K Genome Project to promote personalized medicine through genome sequencing 
and centralized access to health data supported through massive investments in e-health 
to ensure easy secondary uses of health data (Department of Health & Social Care, 2017). 
In the United States, personalized medicine was strongly supported by Senator, later 
President, Obama, leading to the Personalized Medicines Initiative receiving $215 mil-
lion on the President’s 2016 Budget (Fox, 2015; White House Office of the Press 
Secretary, 2015). More importantly, he had already ensured investments of more than 30 
billion USD in interoperability of electronic health records through the stimulus package 
following the financial crisis (Watcher, 2017). As part of these efforts, systems are being 
developed in the United States to provide ‘secure access to the electronic health care 
information of more than 125 million patients’ (U.S. Food and Drug Administration, 
2013: 40). Personalized medicine is thus closely intertwined with creating access to pop-
ulation data.
Denmark is no exception in this regard, but here politicians take pride in already hav-
ing a well-developed digital data infrastructure. Personalized medicine has therefore 
become one of several agendas for which existing health data have come to be seen as an 
important resource. In 2013, the Organisation for Economic Co-operation and 
Development (OECD, 2013) wrote a report in which it pointed out that ‘the goldmine [of 
Danish data] is only partly exploited’ (p. 18). The OECD report has since been refer-
enced in a series of other reports, legal proposals and government plans arguing a need 
for an enhanced health data access and use. Following the OECD report, the Government 
asked the multinational consultancy group Deloitte to advise on how to optimize health 
data use. Pollock and Williams (2010) point to the role of consultancies as ‘promissory 
organisations’ that shape the economy of innovation with self-fulfilling prophecies; in 
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this case, the report really did shape the direction of the investments to come. Deloitte 
(2014) suggested that centralizing data flows would facilitate easier data (re-)use and 
described the overall purpose as a matter of ‘supporting a culture in the health services, 
where the point of departure for medical and health economic actions is based on data 
and knowledge about what works’ (p. 6). It sounds like a laudable idea to build on knowl-
edge about what works, but the report itself is unfortunately a poor example in this 
regard, as I will discuss below. Commissioned consultancy reports such as Deloitte’s 
represent an interesting genre, claiming authoritative insights and thriving on a language 
of ‘recommendations’ but rarely delivering references or other forms of documentation 
(Brenneis, 2006; Christiansen, 2010). The OECD and Deloitte reports serve more as 
sources of authority than as sources of documentation. What has this authority been used 
for and which types of knowledge does it hide?
Centralizing the data infrastructure: Data reuse and its 
blind spots
The Deloitte and OECD reports were used when arguing for a need to establish an inde-
pendent National Board of Health Data and to instigate a number of initiatives aimed at 
centralization of Danish health databases (Lundbergh et al., 2013; Ministeriet for 
Sundhed og Forebyggelse, 2014; Sundhedsdata Styrelsen, 2017). A range of policy 
papers continued to communicate this commitment to infrastructural change focused on 
enhanced accessibility to health data for ‘secondary purposes’; that is, for non-clinical 
purposes (Ministeriet for Sundhed og Forebyggelse, 2013; Registerforskningsudvalget, 
2013). Following up on these initiatives, the Danish Regions developed a general policy 
aimed at ‘optimizing health data usage’ (Danske Regioner, 2015c), again focusing on 
reuse of data for purposes other than treatment of the individual patient. In 2016, a 
national strategy for personalized medicine, also emphasizing centralized access to 
health data, was adopted by both the Ministry of Health and the Danish Regions 
(Sundheds- og Ældreministeriet and Danske Regioner, 2016). In 2016, the commitment 
to enhanced data sourcing was written into the shared budget agreements between the 
three levels of Danish government: ‘The Government, the Municipalities and the Danish 
Regions have agreed to continue the ambitious agenda of digitization’, with a clarifica-
tion that the new strategy aims at ‘development of the data-supported public sector and 
centralized public [fællesoffentlige] digital infrastructures’ (Finansministeriet, 2016: 
23–24). In 2016, they also agreed ‘that personalized medicine in the form of using 
genetic and other forms of molecular information constitute a potentially important ele-
ment in the development of future offers in the health services’ (Regeringen and Danske 
Regioner, 2016: 10). To this end, and with the national strategy for personalized medi-
cine, a new National Genome Centre was funded with 100 million DKK in 2017–2020. 
The money was given with the explicit hope of facilitating additional private research 
donations (see more about the envisioned large-scale project below). In many ways, 
bioinformatics is now seen as the way to finally deliver on all the old promises of genom-
ics that never really materialized (Salter and Salter, 2017). New promises can be made 
by adding enhanced IT data infrastructure to genomics. The abundance of Danish health 
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data is in this way now used to reinvigorate the promise of genomics. Promises have 
social lives and change over time; but while promises continue to relate to the future, 
their political power operates in the presence, as Hedgecoe (2004) argues.
All of these policies consistently emphasize reuse of data and the establishment of 
centralized access points. For example, several agencies work to pool data from the very 
detailed Danish quality assurance databases to open them up for multiple purposes; the 
National Board of Health Data requested copies of these data that are otherwise kept at 
the Regional level. One woman, who I here call Mona and who has worked for years 
with quality databases at the Regional level, explained her perception of the ambitions in 
this way:
Now they want to pool the data, and then you’ve suddenly got, so to say, a hell of a lot 
information about all citizens in Denmark. There might be ten [citizens] who are not registered 
somewhere, but then they must be born abroad, really … Then combining all these data sources 
we can actually have sort of a constant state-of-health registry, which provides us with a real-
time picture of the state of health in the population: How many smoke, what do people weigh, 
how much do they exercise?
Mona found it worrisome that she could not identify a clear purpose for this centraliza-
tion. Besides personalized medicine, Mona had heard mention of using data for new 
forms of personalized prevention strategies, and for calculating remuneration of public 
hospitals according to health outcome measures (so-called ‘value-based healthcare’). 
With data pooling, she noted, you can easily identify those in need of prevention: ‘For 
example, the fattest women live in [the city of] Randers, and they really do, and then I 
guess it could be relevant for Randers to know.’ But she then returned to the absence of 
a clear purpose, remarking that all this data pooling could make her feel a little uncom-
fortable and remind her of ‘“Big Brother” … The reason I am a tiny bit worried is that 
they can’t say why they want all this data. They just want it.’ I do not pursue the issue of 
surveillance here (Lyon, 2019; Zuboff, 2019). I use these quotes primarily to show how 
population databases still allow singling out individuals – and to illustrate the scale of the 
data pooling and how diffuse the purposes remain for many of the involved.3 The pur-
poses should materialize in an unspecified future.
If data reuse is supposed to facilitate decisions ‘based on data and knowledge about 
what works’, as the Deloitte (2014) report suggests, it is remarkable how these policies 
avoid particular forms of existing knowledge about the typical effects of data reuse and 
data pooling. It is well-known that reuse of data for new purposes tends to affect data 
validity and thereby the usefulness for ‘primary purposes’ (Jirotka et al., 2013; Markus, 
2001). That is, data reuse necessitates standardization, which inflicts new forms of hid-
den data errors, and reuse can have looping effects when health professionals change 
their mode of documentation in response to learning that data is used to monitor their 
behaviour (Wadmann et al., 2018, 2013). Such STS-oriented insights are consistently 
ignored in the policy papers. Hence, the quest for ‘evidence’ through data integration, 
which we see in the Deloitte report and the other policies, chooses particular forms of 
evidence and disregards others (Wiener and Kayser-Jones, 1989).
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Mobilizing a sense of need for ‘personalized medicine’
During the scientific conferences on personalized medicine I have attended, researchers 
and politicians seek to mobilize commitments, not so much through the use of data, but 
through narratives. Again and again I have heard speakers refer to the story of President 
Kennedy ‘putting a man on the moon’ to argue the need for political commitment in rela-
tion to ‘personalized medicine’. Similarly, speakers refer to the business school narrative 
of ‘burning platforms’ (a metaphor of fire at an oilrig, often used in management courses 
to signal immediacy of action) and to the latest fashion in innovation, ‘disruptive tech-
nologies’. Disruption is a term used to explain the sudden death of certain technologies: 
Kodak, for example, did not manage to foresee a shift to digital cameras. Paradoxically, 
these narratives are employed to argue the need for data sourcing so that future decisions 
can build on data rather than stories. The burden of evidence rests with the future; in the 
present a good narrative will do.
What is it policymakers and researchers seek to mobilize funding for? In their ‘action 
plan’ for personalized medicine (Danske Regioner, 2015b), the Danish Regions endorsed 
a project strategy of whole genome sequencing of thousands of citizens, in the expecta-
tion that the work would be financed primarily through a donation from the private Novo 
Nordic Foundation (Pedersen, 2015). The specific project plan contains few details 
(Skøtt et al., 2015). Though it is expected to raise several billion Danish kroner of 
research investments, it is a policy document without a clear project protocol. In 2018, 
the foundation nevertheless decided to donate one billion DKK (149 million USD) to the 
construction of sequencing and supercomputing facilities nested within the publically 
controlled National Genome Centre.
What these documents miss in terms of specificity, they make up for in terms of the 
gravity with which they argue the need for investments in personalized medicine. One 
graphic in particular, which I discuss in detail below, serves this purpose. It is consist-
ently presented not only in reports, but also at conferences and in workshops, sometimes 
by several speakers during the same event – to the point where it is introduced with vari-
ations of ‘you probably all know this figure’, and often with the heading: ‘The burning 
platform’ (see Image 1).
The Graphic lists ‘the share of patients who gain no benefit from drugs’ in relation to 
nine diseases. It is said, for example, that 43% of diabetes patients and 75% of cancer 
patients gain no benefit from existing treatment options. It is an astonishing set of claims, 
not least considering that patients do live with diabetes (and other diseases on the list) for 
many years.
This stated lack of evidence for existing treatments is said to explain why we need 
personalized medicine. A more pressing point, in my view, is that The Graphic itself 
lacks evidence. The Danish report from 2015, in which it first appears, references a Food 
and Drug Administration (FDA) report from 2013 as source (U.S. Food and Drug 
Administration, 2013). The FDA report (and a very similar graphic) was used by 
President Obama to promote personalized medicine in the United States (Fox, 2015). 
The FDA sounds like an authoritative source, but the report merely references an article 
from 2001 in support of the claims contained in The Graphic (Spear et al., 2001). One 
could have expected more recent documentation, perhaps, on which to build the future of 
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medicine. When reading the 2001 article, however, the evidence base dwindles even 
more. The 2001 study presents no methodological explanation, and actually just lists 
some numbers in a table in relation to an argument about what it would take to develop 
pharmacogenetic tests (see Senn, 2014 for criticism from a statistician). Furthermore, 
there are some interesting leaps in each translation. The 2001 article referred to ‘[r]
esponse rates of patients to a major drug for a selected group of therapeutic areas’, 
whereas FDA uses the caption ‘for whom drugs are ineffective’. The leap from ‘response 
rates to a major drug’ (drug in singular) to the FDA coinage ‘for whom drugs are ineffec-
tive’ (drugs in plural) to the Danish claim about ‘no benefit’ is remarkable (see Table 1). 
In essence, this means that the claim that there is no evidence for the effect of existing 
treatments is being made without supporting evidence.
As I realized that there was a lack of empirical support for The Graphic, I took the 
opportunity during a conference break to remark to a speechwriter for one of the politi-
cians who had just used this graphic that they ought to stop using it. To my surprise, she 
replied, ‘But it illustrates the problem so well’. While I first could not agree that it illus-
trated anything, I have now come to think that it illustrates how proponents of data sourc-
ing initiatives do not need evidence in support when arguing their case: They can make do 
with a narrative that merely appears to rest on data and a promise of better evidence in the 
future. Instead of using displays of data and evidence to make politics and biomedicine 
accountable, accountability is here directed toward the potential future outcome (a sup-
posedly great project), rather than faithful representation of what is already known.
In October 2016 a reference group of Danish scientific experts delivered a report on 
personalized medicine that finally seemed to have at least wondered about the accuracy 
of The Graphic. The experts added a footnote to it:
It is noted that The Graphic builds on older and not fully compatible data for each area of 
disease, therefore it cannot be said to be fully documented and probably misses the significant 
Image 1. A photo from one of the conferences displaying The Graphic (reproduced on the 
left) that lists ‘Share of patients who gain no benefit from drugs’ (referencing the FDA report).
The Graphic is used in reports and an endless number of talks to argue the need for personal-
ized medicine, here with the heading (in Danish): ‘The burning platform’.
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progress in treatment in recent years based partly on the introduction of new personalized/
stratified drugs (Sundheds- og Ældreministeriet, 2016: 6).
Note, however, that what first looks like acknowledgement of the lack of scientific sup-
port turns out to reinstate the assumption that it builds on evidence (although this might 
be outdated) and ends with the claim that ‘personalized/stratified drugs’ do deliver better 
results. Uncertainty about past knowledge is used to argue the need for future certainty.
I have dwelled at length on The Graphic to illustrate how scientists become complicit 
in a paradoxical evidence-free pursuit of evidence. The absence of interest in understand-
ing the problem (the evidence base today) in order to promote a solution (personalized 
genomic medicine) involves a particular temporality. The solution is basically just a 
promise for the future, but it is so grand that it becomes unnecessary to probe the prob-
lems supposedly haunting the present. And, really, why should scientists who are work-
ing in the nexus of science and policy want to debunk a figure that might help raise 
billions of research funding for a large-scale data-gathering project?
Table 1. A systematic comparison of statements in the graphic(s).
Spear et al. (2001) FDA report (U.S. 
Food and Drug 
Administration, 2013)
Danish report 
(translated)
Framing of tables “Response rates of 
patients to a major drug 
for a selected group of 
therapeutic areas” (p. 202)
“Percentage of 
patients for whom 
drugs are ineffective” 
(p. 12)
“Share of patients 
who gain no benefit 
from drugs”
Unit used in tables Efficacy rate (%) Rate of ineffective 
drugs (%)
Patients gaining no 
benefit (%)
Therapeutic areas 
as listed in tables 
(including spelling 
mistakes)
Depression (SSRI) (62) Depression (38) Depression (38)
Asthma (60) Asthma (40) Asthma (40)
Cardiac arrythmias (60) Cardiac arrhythmias 
(40)
Cardiac 
arrhythmias (40)
Diabetes (57) Diabetes (43) Diabetes (43)
Migraine (acute) (52) Migraine (48) Migraine (48)
Migraine (prophylaxis) (50)
Rheumatoid Arthritis (50) Arthritis (50) Arthritis (50)
Osteoporosis (48) Osteoporosis (52) Osteoporosis (52)
Alzheimer’s (30) Alzheimer’s (70) Alzheimer’s (70)
Oncology (25) Cancer (75) Cancer (75)
HCV (47) (Not in FDA report) Not in Danish report
Schizophrenia (60)
Analgesics (Cox-2) (80)
Incontinence (40)
Note in particular how the delineation of therapeutic areas do not align, how ‘efficacy rate’ has been 
translated into ‘rate of ineffective drugs’ and how Spear et al.’s (2001) identification of ‘a major drug’ within 
selected area has been expanded to all drugs within the area.
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At one of the conferences I attended, I heard a researcher ask critical questions and 
complain that large-scale, top-down initiated projects of this type could get funded with-
out proper scientific evaluation. It was a rare exception to what is otherwise a strikingly 
homogenous scene of enthusiastic debates about the potential of personalized medicine. 
However, one of the key actors at the administrative level in the Danish Regions silenced 
the critique saying: ‘In my experience, scientists always grumble, but once the music is 
playing, they turn towards the orchestra.’ He seems to have construed a new version of 
the old saying, ‘he who pays the piper calls the tune’ – and considering the general lack 
of interest among researchers in challenging the politically presented ‘evidence’, he 
seems to have had a point.
Despite all these reservations, it would be foolish to assume there are no valid scien-
tific arguments for embarking on large-scale projects aimed at a more data-intensive 
form of research. Yet, the political process does not depend on such arguments. The quest 
for centralized data sourcing that is said to be ‘supporting a culture in the health services, 
where the point of departure for medical and health economic actions is based on data 
and knowledge about what works’ (Deloitte, 2014) is itself remarkably resistant to exist-
ing data and knowledge. This is no less true when it comes to the political promises 
related to the economic effects of an investment in personalized medicine. It is to these 
promises I now turn.
Make money or save money?
At conferences, politicians respond to the current sense of crisis of escalating healthcare 
budgets, claiming that personalized medicine will do two good things for the economy: 
It will generate new revenue in the private pharmaceutical industry (make money) and 
cut expenditure in the public healthcare sector (save money). It is apparently both a busi-
ness opportunity and a response to rising healthcare expenditure. Both promises are pre-
sent also in consultancy reports (Deloitte, 2014) and the public action plans and policy 
papers (Danske Regioner, 2015a, 2015c).4 There is, however, a striking paradox at play. 
Denmark is a welfare state where the public sector that hopes to make savings also pays 
for the services that the private sector is expected to make money on. Again, ‘personal-
ized’ medicine serves as a vague but appealing buzzword (Vincent, 2014) onto which 
both ambitions can be projected and their conflict ignored. Furthermore, the cost of data 
sourcing is rarely considered in relation to personalized medicine. I interviewed a data 
analyst, Liselotte, who wrote off the costs associated with data collection: ‘Basically, I 
couldn’t care less [jeg er fløjtende ligeglad] about the economy from where I’m sitting 
… I just want [the data] that I need at my disposal.’ None of the data analysts I inter-
viewed were aware of anyone counting the costs associated with collecting the data they 
used. In official reports and financial bills listing such costs they typically figure as 
‘investments’, which implies a future return. Hence, economic aspects of data sourcing 
are, again, embedded in a particular temporality. Promissory data can be claimed to 
involve potential future savings and gains in ways that overrule concerns about the 
expenses related to data collection in the present.
In pursuit of future economic growth – the aim of making money – the Danish Regions 
commissioned a report from a consultancy named DAMVAD to outline the financial 
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prospects in case of an investment in personalized medicine (DAMVAD Analytics, 
2016). Just like the OECD and Deloitte reports discussed above, this report serves more 
as a source of authority than a form of documentation, giving few references or verifiable 
calculations. It states that with few companies in the area, personalized medicine is not 
an obvious focus for public investment; however, because of the abundance of available 
health data in Denmark, it is an area of ‘great potential’. This potential, apparently, does 
not need further proof (Taussig et al., 2013).
The means by which personalized medicine is to rescue the state from escalating 
healthcare costs – help save money – are similarly undefined and diffuse. The escalating 
costs leading to the current crisis in healthcare expenses partly reflect increased activity 
(due to changing demographics and treatment expectations) and rising costs of pharma-
ceutical products. In some cases, such as cancer treatments, the higher prices are directly 
related to drug regimens associated with ‘personalized medicine’ (Annas, 2014). It is 
partly the rare and the ‘tailored’ treatments that put strains on hospital budgets (COWI, 
2009; Sonne, 2016). At one conference, during a plenary discussion, I therefore com-
mented from my place in the audience that personalized medicine could not both save 
public money and make private money, but I was told from the podium by a prominent 
politician that my ‘thinking was much too narrow’, and that savings would come from, 
for example, ‘a quick return for patients to the job market’. However, even this argument 
suffers when considering that at least 68% of the most expensively treated patients caus-
ing strains on budgets are on permanent welfare and will never return to a job (Region 
Sjælland, 2014).
Praise of prevention as a source of cost-saving is also recurrent in reports and action 
plans. Prima facie, this sounds reasonable. However, the life-expectancy in most high-
income countries has been going up (indicating a better state of public health), without 
the cost of the health services decreasing (Vallgårda et al., 2014): Better health might not 
necessarily mean cheaper health. A group of Dutch health economists (van Baal et al., 
2008), have even argued that prevention of smoking and obesity in modern welfare states 
does not limit expenditure because people will survive to get more expensive long-last-
ing disease patterns. As they note: ‘The underlying mechanism is that there is a substitu-
tion of inexpensive, lethal diseases toward less lethal, and therefore more costly, diseases’ 
(van Baal et al., 2008: 245).
My point is not to dispute the potential gains from personalizing medicine and pre-
vention. Rather, it is that the politicians who so enthusiastically emphasize a need for 
intensified data sourcing to reach these gains do little to engage existing data and knowl-
edge when articulating the economic implications of their proposed investments. What is 
more, some politicians apparently doubt that personalized medicine will imply higher 
prices and levels of healthcare costs. Yet this was considered an unquestionable fact by 
the industry representatives with whom I have been speaking. Several of them even con-
sidered it a key threat to innovation, should the public sector refuse to pay the escalating 
prices. Dumit (2012) has described earlier strategies of mass pharmaceuticalization as a 
way to ensure consistently high annual growth rates in the pharmaceutical sector, but my 
interlocutors in the industry suggest that there is a limit to the number of drugs the aver-
age citizen can take (not least granted the current problematization of the damages of 
polypharmacy). Therefore, they see a need to focus on higher prices instead to sustain 
14 Social Studies of Science 00(0)
continued growth rates. With personalized medicine as one possible solution to the 
growth problem, Hedgecoe (2004: 122) noted more than a decade ago the industry’s dis-
like of cost-effectiveness analyses in this field. Over lunch at one of the recent high-
profile conferences, I joined the table of the representatives from the pharmaceutical 
company sponsoring the event. I quickly realized that they all worked in marketing and 
that there were no participating company scientists. When I asked them why they spon-
sored this type of event, they explained how the whole pricing system is being reconfig-
ured, and that many of their new products were of value to so few people that unless it 
was possible to create ‘a sense of need for “personalization” among clinicians and in the 
public’, they simply would not be able to charge a price that made innovation worth-
while. Conferences on personalized medicine, then, are used to orchestrate this sense of 
need (see also Wu, 2016).
At other events, industry representatives explained their support of personalized med-
icine conferences as a means to ensure their access to healthcare data, so that they could 
develop more precise diagnostic tools and treatments. If they are to make money, access 
to the raw material of personalized medicine – population data – was necessary. Teis, a 
man I interviewed about his work with data integration through a national e-health por-
tal, explained how some big Danish companies now wanted the authorities to facilitate 
the upload of data streams from so-called wearables (including the iPhone) to the public 
platform. This would allow citizen-generated data to be linked to public data using the 
personal identity number (and thereby a calculus of the segments of the population from 
whom the data stem). The companies hope that this form of big data might assist the 
approval process for new drugs by delivering data on the effect of drugs outside the trial 
settings, while authorities hope that such links can in turn deliver what is now increas-
ingly referred to as ‘real-world evidence’ of drug effect.
Teis, in fact, has a different vision. He hopes it can also serve as tools for citizens: ‘We 
have to have some algorithms that analyse the data streams [from wearables]. Draw out 
insights, save those insights, and give those insights back to the citizen.’ This he sees as 
the essence of personalized medicine, citizens contributing to the population and simul-
taneously learning about themselves from population data. From Teis’ perspective, the 
public health system will break down if people do not learn to control their own health. 
Once a data infrastructure of this kind is in place, Teis assumes that data can be used by 
companies and clinicians too. In fact, it is probably the easiest way to get approval. 
Though the companies expect to use such data to prove the worth of more expensive 
products, Teis doubts this outcome; on the contrary, he hopes to prove that more expen-
sive drugs do not fare better.
In a welfare state like Denmark, data-intensive personalized medicine in this way 
operates in a space created by an ambivalent state of crisis (escalating costs and health-
care needs) and opportunity (industry interests). To retain the privilege of health, wealth 
and universal access to care, the state now frames data on its citizens as assets (Sadowski, 
2019; Vezyridis and Timmons, 2017). The value of these assets lies in future use. As 
described above, data are also seen as essential to realizing the other Ps in P4 medicine: 
predictive, preventive and participatory technologies. In the Deloitte (2014) report that 
gave rise to the restructuring of the data infrastructure, several of the competing 
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ambitions are combined in a remarkable bullet point stating the following aims for data 
centralization (in a language no less peculiar in Danish than in its translation):
Targeted support of interconnecting [tværgående] coordination as well as citizens’ own 
involvement in the management of their own disease holds great potential in terms of limiting 
the need for activity in the health services through prevention and changed division of labour 
with the citizens. This could be supported by systematically identifying [udsøgning] the citizens 
who could benefit hereof. The implementation of citizen-directed programs can contribute to 
address inequality in health (Deloitte, 2014: 46).
The pleonasm, ‘interconnecting coordination’ and what in Danish is in fact a neologism, 
‘udsøgning’, which I have translated simply as ‘identifying’ (though it does not have the 
same secret-service-surveillance connotations) are part of this characteristic consultancy 
jargon that elevates plain statements about patients needing to care for themselves to 
slightly obscure truths. Again, the consultancy report manages to state a potential with no 
references, no data and no argumentation in its support. Nevertheless, this aim was 
immediately imported into a government health policy program called ‘The Sooner the 
Better’ [Jo før, jo bedre] (Regeringen, 2014) with a program ‘investment’ of 5 billion 
DKK in the period 2015–2018. Thought of as ‘investments’, the costs associated with 
data might be concrete burdens in the present, lifted only through an unspecific future 
promise of savings.
Personalized medicine is thus expected to make money by making persons contribute 
data that can attract investments, and then save money by using the same data to enhance 
treatment opportunities and to identify the most costly citizens before they become very 
ill, to present them with responsibilities for life-style changes (see also Broer and 
Pickersgill, 2015). I now turn to these new forms of personalized prevention in which 
Teis, Deloitte and Government policies invest so much hope. In doing so, I address how 
the promise of using population data to target individuals is made while selectively pick-
ing and choosing from existing knowledge about effective public health interventions.
Personalized prevention: Making those ‘at risk’ do their 
share
The stated aim of the government programme ‘The Sooner, the Better’ was ‘earlier diag-
nosis, better treatment, and more years in good health for all’ (Regeringen, 2014). One of 
the programme’s methods, in line with Deloitte’s (2014) recommendation, calls for data-
analysis to deliver ‘targeted health check-ups … and support to the most complex and 
vulnerable patients’ (p. 22). Furthermore, it was pointed out that physicians in general 
practice ‘need new IT-based tools to support them in detecting citizens with a high risk 
of chronic illness [so that they can conduct] a targeted health examination’ (p. 25). It is 
in many ways a classic biopolitical move to ask GPs to use population data to identify 
high-risk citizens, who are then encouraged to assume responsibility for their own health 
(Foucault, 1994; Rose, 2007). It is, however, more than that. It is indicative of a new 
political organization: GPs have not previously been allowed to use population databases 
to identify and reach out to citizens who have not themselves requested medical 
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assistance. ‘The Sooner, the Better’ thereby introduces a radical shift in the role of the 
GPs. Rather than waiting for sick people to ask for help, they must seek out at-risk indi-
viduals and make them realize that they will one day have a problem. GPs are self-
employed in Denmark, but citizens can use them for free, as the expense is covered by 
the Danish Regions. Partly for this reason, it has always been a basic principle that GPs 
should not initiate contact with patients because they could use it to boost their business. 
The Danish health system, with its universal access to care, was set up in a period with a 
focus on treatment and cure, where the obligation resting on the sick was to follow the 
advice of the system until the point of recovery (Parsons, 1951). The personalized data-
intensive identification thereby forms part of a wider shift in not only healthcare tasks, 
but also in the responsibilities of GPs and citizens.
This type of personalized medicine can be said to address inequality in health using 
data-intensive methods to identify and target those with the most pressing need. Though 
congruent at some level with the US and British versions that put the concept of person-
alized medicine on the international agenda (Hedgecoe, 2004; Hogle, 2016a; Macfall, 
2019; Reardon, 2011), this type of ‘personalization’ still takes on a form of its own. In 
Denmark, for example, no one stands to lose access to health or insurance eligibility; in 
fact, they can expect to receive more, rather than less, attention. The emphasis on ‘soli-
darity’ in the Danish system instead implies an unequal distribution of the obligation to 
change (Prainsack, 2014). That is, it is those citizens who are living with the most risk 
factors who are the most obliged to change their life-style. The ‘personalized’ fight 
against inequality in health then becomes a personal responsibility for conforming to the 
norm, very personal indeed (Árnason, 2012). In this way, the potential future ill-health of 
‘costly’ individuals’ makes them accountable in the present to the wider Danish 
population.
This Danish type of personalized prevention provides little room for taking into 
account personal circumstances and preferences (Prainsack, 2014). Though personalized 
medicine once emerged as a term in the early 20th century to challenge the increased 
reliance of statistical evidence, today it has become almost synonymous with data-inten-
sive medicine (Tutton, 2014). The person as a carrier of values and experiences has been 
transformed into a source of data and a target for intervention. In an interview with my 
colleague Sarah Wadmann and me, a Danish GP commented on the current shift towards 
computer-based medical advice. She complained that there was no need for a doctor 
anymore, just a computer, before saying with real agitation in her voice:
I think it’s bloody annoying that they act as if they have a monopoly on, you know, this 
‘personalized medicine’. Really, it’s such an abuse, it’s as if we’re sort of molesting [voldtager] 
the meaning of the word, right? ’Cause it’s, God damn it, not what the rest of us mean with 
‘personal’ attention, right? We don’t mean statistical average!
Data-intensive methods and decision-support systems clearly provide important medical 
tools, but this GP also sees them as intervening in her perception of good care – in effect 
undermining personalization.
While medical examinations may lead to more treatment for those targeted by the 
algorithms for risk identification, the effect of medical examinations on the health of 
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those identified is contested.5 This is also the case in relation to preventive counselling 
on behavioural change. In fact, existing studies mostly indicate that this has a limited 
effect (Hollands et al., 2016; Jørgensen et al., 2014). The majority of citizens targeted 
suffer from complex combinations of social inequalities, not lack of advice (Marmot et 
al., 2010). Furthermore, it is striking that concurrent with the introduction of data-driven 
‘targeted’ prevention, the very same groups targeted in this manner in Denmark have had 
their social and unemployment benefits reduced. ‘Data-driven decision-making’ thereby 
glosses over the grim reality that those who are facing health inequalities as a result of 
systematically tightened structural constraints are offered an hour of medical counselling 
in what could perhaps be called a classic example of responsibilization (c.f. Kerr et al., 
2019), not because of but despite existing studies and ‘knowledge about what works’.
GPs have become mediators in this process of responsibilization in the Danish ver-
sion of personalized medicine. Therefore, it is also interesting that a recent study of a 
GP-mediated preventive intervention program in Denmark found that GPs often decide 
to not even mention life-style factors such as smoking to their patients because they do 
not expect any effect, and fear negative implications for patients’ confidence in them 
(Broholm-Jørgensen et al., 2017). As Green and Vogt (2016) argue, if we take all social 
factors into consideration then it is a very long way from the ideal of P4 medicine to 
practical implementation. Still, the promise made by proponents of P4 is that with proper 
data sourcing, we will know the effect – after implementation – despite uncertainties in 
the present.
In sum, personalized data-intensive medicine operates in a remarkable tension 
between ambitions of participatory approaches empowering individuals (using popula-
tion data to identify and guide individuals) and standardized population data (making 
individuals conform to averages). Irrespective of existing studies indicating the limited 
effect of the chosen measures, it thrives on a promise of future effects which are in turn 
dependent on a responsibilization of those currently deemed at risk.
Conclusion
The development of personalized medicine takes multiple forms. As a buzzword, it is 
sufficiently vague to allow different individuals and institutions to project competing 
hopes and expectations onto it. One thing is clear, however: Novel regimens of personal-
ized medicine do not imply abandoning large numbers and the methods of the population 
health sciences. On the contrary, personalized medicine requires bigger datasets than 
ever before. The ‘laboratories of personalized medicine’ are replete with population data. 
When such datasets are constructed and put into use, personalized medicine acquires 
nationally specific forms in reflection of existing healthcare systems and political and 
economic structures. To understand what personalized medicine produces locally, we 
therefore need to follow their translations in specific settings.
The Danish story of mobilizing massive investments in a new research area could be 
told as a classic narrative of the formation and facilitation of political alliances 
(Czarniawska, 2005; Vincent, 2014). To raise funds you need to raise expectations 
(Brown and Michael, 2003), and it is hardly surprising that the boundaries between sci-
entific evidence and political processes become blurry in the articulation of such 
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arguments (Hoeyer et al., 2019; Weiss, 1986). In relation to personalized medicine, I 
nevertheless find it striking how groups of researchers, clinicians and policymakers coa-
lesce in their pursuit of future sources of evidence, while demonstrating tenuous relation-
ships with existing evidence. In the Danish assemblages created around personalized 
medicine, it is as if data serve more as a promise for the future than as inscriptions of the 
past. In this turmoil of politicized uses of ‘evidence’, there is a special role for STS to 
exert a form of data-engaged resistance from within. Rather than accepting a reduction 
of knowledge to questions of power, there is an important task in tracing knowledge 
claims through their cycles of production, use and re-appropriation by new actors for 
new purposes. But this is not enough. STS needs to explore policy processes as sites of 
particular forms of knowledge production with political effects in need of scrutiny in 
their own right. If policymakers today pick and choose among different forms of knowl-
edge depending on their agendas, and if they prefer a quick consultancy report and a 
popular narrative about placing ‘a man on the moon’ to substantial data analysis, we 
should probably not expect their future decision-making processes to become altogether 
different. But this is not the key question. What we need to ask is instead what all the 
promises of future evidence produce in the present.
One important but rarely acknowledged effect of data promises is, I suggest, post-
ponement. Once a policymaker makes a call for ‘more data’, it becomes legitimate to 
postpone action until the data have been collected. By claiming that it is better to wait 
until more data have been accumulated, data promises thus generate a form of temporal 
disruption of public accountability. Talk about the ‘potential’ of future data-intensive 
methods allows the prospects of future knowledge to overrule what we know already, 
and thereby what we could already do – in the present. Responsibility becomes rede-
fined: It is responsible to delay the use of available tools for limiting inequality in health, 
while it becomes irresponsible not to pursue data for future use. Simultaneously, the 
implementation of unproven prevention schemes is legitimized because future data 
might prove their value. Current scientific doubts can thereby be sidestepped and action 
endorsed while making the claim that it is evidence-based medicine. In doing so, the 
temporality of the models that were traditionally referenced in public policy are dis-
rupted because the effects of data sourcing are supposed to become evident only after 
implementation. Data become promissory. Promises embody a particular form of 
accountability through the obligations that they implicitly or explicitly reference. With 
promises of future gains, the welfare state can portray itself as caring for the future of the 
vulnerable and poor, rather than their present. In this context, data-as-promise, or what I 
call ‘promissory data’, is – politically speaking – a more powerful resource than data-as-
evidence. The risk in all of this is that the terms of care come to resemble what Biehl 
(2016) has called a ‘fabulation of power’, a narrative that disregards existing knowledge 
to sustain a myth of governance that has the eradication of inequality as a primary objec-
tive. Faced with such fabulations, data per se seem relatively powerless and unfit to hold 
authorities accountable – unless critical observers learn to reintegrate data in new coun-
ternarratives as a form of data-engaged resistance. My discussion of Table 1 may serve 
as a humble attempt of doing that.
If we acknowledge that there are no easy solutions to the multi-rooted ‘crisis’ associ-
ated with escalating healthcare costs, and that the relevant forms of knowledge for any 
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major social problem will always be contested, we might now appreciate this element of 
the appeal of personalized medicine and the wider field of big data. Promissory data 
deliver legitimate postponement of action – and fill the waiting time with a genuine and 
serious task: data compilation. It is even possible for policymakers to portray themselves 
as siding with key values of accountable governance – dedication to evidence and care 
for those in need – without actually doing anything and while ignoring contemporary 
controversies and uncomfortable insights. Mostly, data collection can be associated with 
goals that few oppose, not least because the realization of these goals remains vaguely 
situated in the future. When proponents of personalization attack the legitimacy of struc-
tural prevention aimed at mass health, for example, they are in-line with a critique that 
has also been made in STS (Dumit, 2012). And who wants to argue against the construc-
tion of a better evidence-base and more effective treatments? Still, STS needs to keep 
scrutinizing whether policymakers are replacing mass health, not with ‘tailor-made med-
icine’, but with new data-intensive technologies of control and responsibilization.
The quest for personalized medicine currently interacts with forms of data-sourcing 
that imply that citizens should serve as data subjects and contribute to population goals 
(Garrety et al., 2013; Green and Vogt, 2016; Vezyridis and Timmons, 2017). While citi-
zens incur this responsibility in the present, the authorities postpone their own responsi-
bility for ensuring good use of data to the future. Therefore, personalized medicine does 
not imply a shift from population to individual; instead, its data-intensive methods gener-
ate new temporal organizations of accountability and new ways of inscribing the popula-
tion in the individual while letting individuals contribute to the population. Public health 
is reconfigured in the process.
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Notes
1. I would like to thank Jeanette Knox for her kind assistance with the more challenging quotes. 
At the time of submitting this manuscript for publication, I am still interviewing, but at the 
point of submission I had interviewed 21 clinicians and data analysts. Formal research inter-
views are ongoing.
2. In support of his argument he references a guide on how to do set up such N-of-1 trials 
(Kravitz et al., 2014). The guide itself suggests setting up individual treatment plans as 
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successive testing of alternative therapeutic options. The scope of the guidance is quite lim-
ited because patients rarely suffer from a single stable condition for which there are two alter-
native treatments. If the leap should be made from assessing effect to predicting effect, this 
type of N-of-1 trial necessitates the pooling of very detailed data in cross-national data infra-
structures to compare similar cases prior to treatment. The reference to a guide on ‘N-of-1 
trials’ thus mostly seems to serve the purpose of stating that statistics can operate at the level 
of individual – the guide is basically about something very different from Schork’s vision of 
personalized medicine.
3. The relevant authorities claim that they simply want a copy of the locally collected data and 
do not plan to use it in the way Mona imagines. In relation to research uses of population 
databases there are restrictions on the identification of individuals, but such restrictions do 
not apply when data are used in clinical practice for identifying those at-risk individuals who 
are invited for medical examinations and preventive counselling. It is legally unresolved how 
to align the two agendas, just as it is impossible to fully delineate all future purposes based on 
current plans.
4. In the national strategy, one sentence does acknowledge some uncertainty: ‘The strategy 
can imply both potential savings and additional costs in the health services’ (Sundheds- og 
Ældreministeriet and Danske Regioner, 2016: 24).
5. There is an ongoing and very fierce debate in Danish public health science environments 
about whether early diagnosis is associated with increased or decreased burdens of disease 
(e.g., Hvas et al., 2009). I will not engage this debate here, but simply note that the authorities 
do not use the studies indicating negative effects of early intervention.
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